2022-09-29-世界卫生组织-A_H3N2_variant_-_Southern_hemisphere_2023_2页_184kb

Summary of Variant Influenza A(H3N2) Candidate Vaccine Viruses and Potency Testing Reagents:

• The development and availability status is reported by the WHO Collaborating Centres (WHO CCs) of the Global Influenza Surveillance and Response System (GISRS), focusing on antigenic and genetic analyses.
• All candidate vaccine viruses have undergone two-way haemagglutination inhibition (HI) testing and are approved by national or regional control authorities for use in vaccines.
• Key candidate vaccine viruses include: A/Minnesota/11/2010 NYMC X-203 (conventional reassortant), A/Minnesota/11/2010 NYMC X-203A (conventional reassortant), A/Indiana/10/2011 NYMC X-213 (reassortant), and A/Ohio/28/2016 ID CDC-RG55C (wild type virus), developed by institutions such as CDC, NYMC, and WHO CCs.
• These viruses can be handled under Biosafety Level 2 (BSL-2) enhanced containment after passing safety evaluations.
• Potency testing reagents are available, with reference antigens provided by sources like CBER/FDA and NIBSC, lot numbers specified.
• New reagents are highlighted and can be requested, subject to evaluation and potential restrictions.
• Contact details are provided for inquiries, including CDC, NIBSC, NYMC, and WHO HQ, along with a link to the full resource. Notable changes are marked in the original document.